Press Coverage

Hepatitis C Treatment: Study Finds No Liver, Kidney or Cardiovascular Adverse Effects

Interview mentions that an ISMP QuarterWatchTM report raising questions about whether direct acting antiviral medications for the treatment of Hepatitis C posed any significant safety risks for patients was the impetus for further study.

For the full text, visit MedicalResearch.com online.

More News

An international medication safety call to action is aimed at preventing fatalities due to medication errors with concentrated potassium injection, inadvertent intraspinal injection of vincristine, and accidental daily instead of weekly dosing of methotrexate in patients with psoriasis or rheumatoid arthritis.